On the other hand, results revealed that upregulation of RNASET2 was associated with disease specific survival (DSS) (HR: 2.20; 1.47–3.28, P < 0.001), overall survival (OS) (HR: 1.87; 1.38–2.55, P < 0.001) and progression-free interval (PFI) (HR: 1.89; 1.37–2.60, P < 0.001) in ccRCC patients (Fig. 2, B and D). This evidence concerns the gene RNASET2 and nonpapillary renal cell carcinoma.